200 related articles for article (PubMed ID: 25744866)
21. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of inflammatory myofibroblastic tumor with malignant transformation by surgical resection and chemotherapy.
Dishop MK; Warner BW; Dehner LP; Kriss VM; Greenwood MF; Geil JD; Moscow JA
J Pediatr Hematol Oncol; 2003 Feb; 25(2):153-8. PubMed ID: 12571469
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
[TBL] [Abstract][Full Text] [Related]
24. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review.
Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA
Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176
[TBL] [Abstract][Full Text] [Related]
26. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
[TBL] [Abstract][Full Text] [Related]
27. "How long does crizotinib work? a rare case of recurrent inflammatory myofibroblastic tumor".
Albayrak HC; Gürler F; Sütçüoğlu O; Akyürek N; Özet A
Anticancer Drugs; 2022 Jan; 33(1):109-111. PubMed ID: 34261914
[TBL] [Abstract][Full Text] [Related]
28. Treatment and detection of ALK-rearranged NSCLC.
Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
[TBL] [Abstract][Full Text] [Related]
29. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
30. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
32. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
Godbert Y; Henriques de Figueiredo B; Bonichon F; Chibon F; Hostein I; Pérot G; Dupin C; Daubech A; Belleannée G; Gros A; Italiano A; Soubeyran I
J Clin Oncol; 2015 Jul; 33(20):e84-7. PubMed ID: 24687827
[No Abstract] [Full Text] [Related]
33. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
[TBL] [Abstract][Full Text] [Related]
34. Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer.
Facchinetti F; Caramella C; Auger N; Planchard D; Adam J; Lacroix L; Remon J; Massard C; Soria JC; Friboulet L; Besse B
Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27197808
[TBL] [Abstract][Full Text] [Related]
35. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
36. Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report.
Liu Q; Wei J; Liu X; Wang J
Medicine (Baltimore); 2019 Dec; 98(52):e18414. PubMed ID: 31876714
[TBL] [Abstract][Full Text] [Related]
37. Intra-abdominal inflammatory myofibroblastic tumours in children--a report of three cases in 3 years.
Gopal M; Tan YW; Wood K; Barrett AM; Hosie GP
Eur J Pediatr Surg; 2012 Jun; 22(3):254-6. PubMed ID: 22576303
[No Abstract] [Full Text] [Related]
38. A cutaneous inflammatory myofibroblastic tumour with ALK rearrangement in the upper extremity.
Cantile M; Aquino G; Franco R; Marra L; Gallo M; De Chiara A
Pathology; 2014 Oct; 46(6):575-6. PubMed ID: 25158817
[No Abstract] [Full Text] [Related]
39. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
40. Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.
Kerner GS; Koole MJ; Bongaerts AH; Pruim J; Groen HJ;
PLoS One; 2016; 11(5):e0149955. PubMed ID: 27137772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]